Product Details
Synonyms
TNFRSF9, 4-1BB, CD137, CDw137, ILA
Source
Human 4-1BB (24-86) Protein, His Tag (41B-H52H9) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Cys 86 (Accession # Q07011-1).
Predicted N-terminus: Leu 24
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 8.7 kDa. The protein migrates as 13 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE

Human 4-1BB (24-86) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA

Immobilized Human 4-1BB / TNFRSF9 (24-86), His Tag (Cat. No. 41B-H52H9) at 2 μg/mL (100 μL/well) can bind UreluMab, Human IgG4 with a linear range of 0.1-2 ng/mL (QC tested).
Protocol
User Reviews Publish Comment

Background Introduction
Frontier Progress
- English Name:
Tumor necrosis factor receptor superfamily member 9
- Category:
- Listed Drugs Count:
0 Details
- Clinical Drugs Count:
77 Details
- Highest R&D Stage:
Phase 3 Clinical



















